$Rapid Regression of Chemotherapy Refractory Lymphocyte Predominant Hodgkin's Disease after Administration of Rituximab (anti CD 20 Monoclonal Antibody) and Interleukin-2$

Rapid Regression of Chemotherapy Refractory Lymphocyte Predominant Hodgkin's Disease after Administration of Rituximab (anti CD 20 Monoclonal Antibody) and Interleukin-2

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia & lymphoma 1999, Vol.35 (5-6), p.641-642
Hauptverfasser:	Keilholz, Ulrich, Szelényi, Hubert, Siehl, Jan, Foss, Hans Dieter, Knauf, Wolfgang, Thiel, Eckhard
Format:	Artikel
Sprache:	eng
Schlagworte:	anti CD20 monoclonal antibody Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Murine-Derived Antigens, CD20 - analysis Antigens, CD20 - immunology Antigens, Neoplasm - analysis Antigens, Neoplasm - immunology Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bleomycin - administration & dosage Carmustine - administration & dosage Cyclophosphamide - administration & dosage Cytarabine - administration & dosage Dacarbazine - administration & dosage Dexamethasone - administration & dosage Doxorubicin - administration & dosage Drug Resistance, Neoplasm Etoposide - administration & dosage Etoposide - analogs & derivatives Hodgkin Disease - drug therapy Hodgkin Disease - immunology Hodgkin Disease - pathology Hodgkin Disease - therapy Humans Idarubicin - administration & dosage Ifosfamide - administration & dosage IL-2 Immunization, Passive interleukin-2 Interleukin-2 - administration & dosage Interleukin-2 - therapeutic use lymphocyte predominant Hodgkins disease Male Melphalan - administration & dosage Middle Aged Prednisone - administration & dosage Procarbazine - administration & dosage refractory Hodgkins disease Remission Induction Rituximab Salvage Therapy tumor regression Vinblastine - administration & dosage Vincristine - administration & dosage
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:
ISSN:	1042-8194 1029-2403
DOI:	10.1080/10428199909169633